Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMGN stock price vs GILD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GILD's multiple
Needs GILD P/E.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
REGENERON PHARMACEUTICALS, INC.
AMGN vs REGN
BIOGEN INC.
AMGN vs BIIB
VERTEX PHARMACEUTICALS INC / MA
AMGN vs VRTX
Moderna, Inc.
AMGN vs MRNA
Eli Lilly and Company
AMGN vs LLY
AbbVie Inc.
AMGN vs ABBV
BRISTOL MYERS SQUIBB CO
AMGN vs BMY
Merck & Co., Inc.
AMGN vs MRK
PFIZER INC
AMGN vs PFE
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMGN's superior operating margins and ROIC will sustain a re-rating toward GILD multiples, then consider initiating or adding to a position because AMGN trades below GILD-implied low ($382.51) while showing stronger profitability (Operating Margin 21.7%, ROIC 36.9%) and larger net income ($4.1B) versus GILD.
AMGN's current price ($341.88) sits below GILD-implied range ($382.51 - $2824.06) and far below GILD-implied P/E-based implied price ($2824.06). The large valuation gap is driven primarily by GILD's extreme P/E (373.6x) versus AMGN's P/E (45.2x), while P/S and EV multiples show a smaller gap.
Supporting Metrics
